甘李药业发布关于胰岛素周制剂GZR4中国Ⅲ期临床试验完成首例受试者给药的公告。当中介绍，GZR4是甘李药业在研的每周皮下注射给药一次的超长效胰岛素周制剂，适应症为糖尿病。GZR4于2022年7月7日获得了中国国家药品监督管理局开展临床试验的批准，20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback